Harmony Biosciences Financial Ratios
NASDAQ: HRMYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Harmony Biosciences ratio analysis
Harmony Biosciences earned a net margin of 18.3% in FY 2025, down from 20.4% a year earlier. Gross margin was 77.2% compared with a median of 80.1% over the prior 6 years. Return on equity reached 18.2%, meaning Harmony Biosciences generated 0.18 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.19 versus 0.27 the year before, and the current ratio was 3.60. At the end of FY 2025, HRMY traded at 13.8 times earnings; across the 5 fiscal years shown, its year-end P/E ranged from 13.8 to 73.5, with a median of 15.2. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Harmony Biosciences financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 13.79 | 13.86 | 15.16 | 18.55 | 73.52 | — | — |
| Price / sales | 2.47 | 2.77 | 3.30 | 7.45 | 8.03 | 5.83 | — |
| Price / book | 2.47 | 3.00 | 4.11 | 8.09 | 13.15 | 9.59 | — |
| Gross margin | 77.2% | 78.1% | 79.2% | 80.9% | 81.8% | 82.6% | 73.7% |
| Operating margin | 24.0% | 26.7% | 33.0% | 27.4% | 28.7% | 10.6% | -2,433.8% |
| Net margin | 18.3% | 20.4% | 22.1% | 41.4% | 11.3% | -23.1% | -2,535.1% |
| Free cash flow margin | 40.1% | 30.6% | 37.6% | 33.0% | 32.2% | -1.9% | -1,260.8% |
| Return on equity (ROE) | 18.2% | 22.1% | 27.6% | 45.0% | 18.5% | -38.0% | — |
| Return on assets (ROA) | 12.5% | 14.6% | 15.9% | 26.9% | 8.0% | -8.7% | -142.4% |
| Debt / equity | 0.19 | 0.27 | 0.41 | 0.48 | 1.03 | 2.00 | — |
| Current ratio | 3.60 | 3.31 | 2.75 | 5.07 | 5.29 | 1.95 | 1.58 |
| Revenue growth | 21.5% | 22.8% | 32.9% | 43.4% | 91.2% | 2,564.6% | — |
| EPS growth | 8.0% | 17.8% | -28.3% | 412.1% | — | — | — |